Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Valuable Targets
6 min read
Latest Developments in the Research and Development of C5 Inhibitor
11 September 2023
C5, or the fifth component of complement, plays a crucial role in the human body's immune system.
Latest Hotspot
3 min read
Tango Therapeutics receives FDA approval for TNG348, a new USP1 inhibitor targeting BRCA1/2-mutant and other HRD+ cancers
11 September 2023
Tango Therapeutics has received FDA clearance for its IND application for TNG348, a new USP1 inhibitor.
Drug Insights
5 min read
Glycopyrrolate: Detailed Review of its Transformative R&D Success, Mechanism of Action
11 September 2023
This article summarized the latest R&D progress of Glycopyrrolate, the Mechanism of Action for Glycopyrrolate, and the drug target R&D trends for Glycopyrrolate.
Latest Hotspot
3 min read
Cidara Therapeutics has announced that Janssen has elected to move forward under their license agreement for novel drug-Fc conjugates targeting influenza
11 September 2023
Biotech company Cidara Therapeutics is developing drug-Fc conjugate immunotherapies for serious diseases. Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, has given Cidara a go-ahead for CD388 (JNJ-0953), a universal prevention solution for influenza A and B.
Drug Insights
4 min read
Etodolac Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
11 September 2023
This article summarized the latest R&D progress of Etodolac, the Mechanism of Action for Etodolac, and the drug target R&D trends for Etodolac.
Valuable Targets
8 min read
BTK inhibitors, a field with promising prospects
11 September 2023
BTK inhibitors can regulate the functions of various immune cells that are crucial to innate and adaptive immune responses.
Latest Hotspot
5 min read
Gloria Biosciences announced that zimberelimab for the treatment of recurrent or metastatic cervical cancer has been successfully listed in China
11 September 2023
Guangzhou Gloria Biosciences has announced that Zimberelimab injection (YuTuo®, GLS-010), has received marketing approval from the China NMPA.
Drug Insights
5 min read
Unleashing the Power of Dicloxacillin sodium: A Comprehensive Review on R&D Breakthroughs
11 September 2023
This article summarized the latest R&D progress of Dicloxacillin sodium, the Mechanism of Action for Dicloxacillin sodium, and the drug target R&D trends for Dicloxacillin sodium.
Valuable Targets
5 min read
Brief Discussion on Clinically Under-Investigation BRD4 Inhibitors
11 September 2023
BRD4 inhibitors target BRD4 for inhibition, which hold tremendous value in anti-cancer and anti-inflammatory sectors, as well as many other fields.
Latest Hotspot
4 min read
SpliSense has successfully concluded the Phase 1 clinical trial of SPL84, an RNA-based therapy aimed at treating Cystic Fibrosis
11 September 2023
SpliSense declared the successful completion of a Phase 1 clinical trial for SPL84.
Drug Insights
4 min read
A Comprehensive Review of Cinacalcet hydrochloride's R&D Innovations
11 September 2023
This article summarized the latest R&D progress of Cinacalcet hydrochloride, the Mechanism of Action for Cinacalcet hydrochloride, and the drug target R&D trends for Cinacalcet hydrochloride.
Latest Hotspot
3 min read
Verismo Therapeutics provides SynKIR-110 treatment for the first advanced cancer patient in clinical trials
11 September 2023
Verismo Therapeutics, a clinical-stage company specializing in CAR-T therapies, has initiated the dosing of the first patient in their STAR-101 clinical trial.